nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—CYP2C9—brain cancer	0.48	1	CbGaD
Fluoxetine—CYP2D6—Lomustine—brain cancer	0.0504	0.191	CbGbCtD
Fluoxetine—CYP1A2—Carmustine—brain cancer	0.0499	0.189	CbGbCtD
Fluoxetine—CYP2D6—Hydroxyurea—brain cancer	0.0382	0.145	CbGbCtD
Fluoxetine—CYP3A4—Temozolomide—brain cancer	0.0377	0.143	CbGbCtD
Fluoxetine—CYP3A4—Lomustine—brain cancer	0.0321	0.122	CbGbCtD
Fluoxetine—CYP3A5—Etoposide—brain cancer	0.0199	0.0754	CbGbCtD
Fluoxetine—CYP1A2—Etoposide—brain cancer	0.0148	0.0561	CbGbCtD
Fluoxetine—ABCB1—Etoposide—brain cancer	0.0129	0.0491	CbGbCtD
Fluoxetine—HTR2C—choroid plexus—brain cancer	0.00912	0.146	CbGeAlD
Fluoxetine—CYP3A4—Etoposide—brain cancer	0.00775	0.0294	CbGbCtD
Fluoxetine—HTR2A—choroid plexus—brain cancer	0.00457	0.0733	CbGeAlD
Fluoxetine—HTR2C—telencephalic ventricle—brain cancer	0.00267	0.0428	CbGeAlD
Fluoxetine—HTR2A—trigeminal nerve—brain cancer	0.00231	0.0371	CbGeAlD
Fluoxetine—HTR2A—cerebellar cortex—brain cancer	0.0023	0.0369	CbGeAlD
Fluoxetine—HTR2A—vein—brain cancer	0.00209	0.0335	CbGeAlD
Fluoxetine—HTR2C—ganglion—brain cancer	0.00166	0.0267	CbGeAlD
Fluoxetine—HTR2A—cranial nerve—brain cancer	0.00165	0.0264	CbGeAlD
Fluoxetine—HTR2A—pons—brain cancer	0.00163	0.0261	CbGeAlD
Fluoxetine—SLC6A4—ganglion—brain cancer	0.00158	0.0253	CbGeAlD
Fluoxetine—SLC6A2—ganglion—brain cancer	0.00139	0.0223	CbGeAlD
Fluoxetine—HTR2A—telencephalic ventricle—brain cancer	0.00134	0.0215	CbGeAlD
Fluoxetine—SLC6A4—hindbrain—brain cancer	0.0012	0.0192	CbGeAlD
Fluoxetine—HTR2A—pineal body—brain cancer	0.00116	0.0186	CbGeAlD
Fluoxetine—HTR2A—ganglion—brain cancer	0.000834	0.0134	CbGeAlD
Fluoxetine—HTR2C—brainstem—brain cancer	0.000723	0.0116	CbGeAlD
Fluoxetine—HTR2A—endothelium—brain cancer	0.000719	0.0115	CbGeAlD
Fluoxetine—SLC6A4—brainstem—brain cancer	0.000685	0.011	CbGeAlD
Fluoxetine—HTR2A—blood vessel—brain cancer	0.000663	0.0106	CbGeAlD
Fluoxetine—HTR2C—telencephalon—brain cancer	0.000641	0.0103	CbGeAlD
Fluoxetine—HTR2A—hindbrain—brain cancer	0.000632	0.0101	CbGeAlD
Fluoxetine—SLC6A4—telencephalon—brain cancer	0.000608	0.00975	CbGeAlD
Fluoxetine—SIGMAR1—telencephalon—brain cancer	0.000604	0.00968	CbGeAlD
Fluoxetine—SLC6A2—brainstem—brain cancer	0.000603	0.00967	CbGeAlD
Fluoxetine—CYP2D6—hindbrain—brain cancer	0.000576	0.00924	CbGeAlD
Fluoxetine—SLC6A2—telencephalon—brain cancer	0.000535	0.00858	CbGeAlD
Fluoxetine—HTR2C—medulla oblongata—brain cancer	0.000504	0.00808	CbGeAlD
Fluoxetine—ORM1—spinal cord—brain cancer	0.0005	0.00802	CbGeAlD
Fluoxetine—SIGMAR1—pituitary gland—brain cancer	0.000492	0.00789	CbGeAlD
Fluoxetine—SIGMAR1—medulla oblongata—brain cancer	0.000474	0.00761	CbGeAlD
Fluoxetine—HTR2C—midbrain—brain cancer	0.000461	0.00739	CbGeAlD
Fluoxetine—ORM1—endocrine gland—brain cancer	0.00045	0.00722	CbGeAlD
Fluoxetine—HTR2C—spinal cord—brain cancer	0.000449	0.00721	CbGeAlD
Fluoxetine—SLC6A2—gonad—brain cancer	0.000447	0.00716	CbGeAlD
Fluoxetine—SLC6A4—midbrain—brain cancer	0.000437	0.007	CbGeAlD
Fluoxetine—ABCB1—blood vessel—brain cancer	0.000435	0.00697	CbGeAlD
Fluoxetine—SIGMAR1—midbrain—brain cancer	0.000434	0.00695	CbGeAlD
Fluoxetine—SLC6A4—spinal cord—brain cancer	0.000426	0.00683	CbGeAlD
Fluoxetine—SIGMAR1—spinal cord—brain cancer	0.000423	0.00679	CbGeAlD
Fluoxetine—SLC6A2—medulla oblongata—brain cancer	0.000421	0.00675	CbGeAlD
Fluoxetine—ORM1—central nervous system—brain cancer	0.000406	0.0065	CbGeAlD
Fluoxetine—HTR2C—head—brain cancer	0.000399	0.0064	CbGeAlD
Fluoxetine—SLC6A4—endocrine gland—brain cancer	0.000383	0.00615	CbGeAlD
Fluoxetine—SLC6A4—head—brain cancer	0.000379	0.00607	CbGeAlD
Fluoxetine—HTR2C—central nervous system—brain cancer	0.000365	0.00585	CbGeAlD
Fluoxetine—HTR2A—brainstem—brain cancer	0.000363	0.00581	CbGeAlD
Fluoxetine—SLC6A4—central nervous system—brain cancer	0.000346	0.00554	CbGeAlD
Fluoxetine—SLC6A2—endocrine gland—brain cancer	0.000338	0.00541	CbGeAlD
Fluoxetine—SIGMAR1—cerebellum—brain cancer	0.000335	0.00538	CbGeAlD
Fluoxetine—SLC6A2—head—brain cancer	0.000333	0.00535	CbGeAlD
Fluoxetine—CYP2D6—brainstem—brain cancer	0.00033	0.0053	CbGeAlD
Fluoxetine—CYP2B6—gonad—brain cancer	0.000329	0.00528	CbGeAlD
Fluoxetine—HTR2A—telencephalon—brain cancer	0.000322	0.00516	CbGeAlD
Fluoxetine—CYP2C19—endocrine gland—brain cancer	0.000318	0.0051	CbGeAlD
Fluoxetine—SLC6A2—central nervous system—brain cancer	0.000304	0.00488	CbGeAlD
Fluoxetine—CYP2D6—telencephalon—brain cancer	0.000293	0.0047	CbGeAlD
Fluoxetine—HTR2C—brain—brain cancer	0.000289	0.00464	CbGeAlD
Fluoxetine—ALB—brain—brain cancer	0.000282	0.00453	CbGeAlD
Fluoxetine—SLC6A4—brain—brain cancer	0.000274	0.0044	CbGeAlD
Fluoxetine—SIGMAR1—brain—brain cancer	0.000272	0.00437	CbGeAlD
Fluoxetine—HTR2A—gonad—brain cancer	0.000268	0.00431	CbGeAlD
Fluoxetine—HTR2A—pituitary gland—brain cancer	0.000262	0.0042	CbGeAlD
Fluoxetine—CYP1A2—endocrine gland—brain cancer	0.00026	0.00416	CbGeAlD
Fluoxetine—HTR2A—medulla oblongata—brain cancer	0.000253	0.00405	CbGeAlD
Fluoxetine—CYP3A5—endocrine gland—brain cancer	0.00025	0.00401	CbGeAlD
Fluoxetine—CYP2B6—endocrine gland—brain cancer	0.000249	0.00399	CbGeAlD
Fluoxetine—CYP2C9—endocrine gland—brain cancer	0.000246	0.00395	CbGeAlD
Fluoxetine—CYP2B6—head—brain cancer	0.000246	0.00394	CbGeAlD
Fluoxetine—SLC6A2—brain—brain cancer	0.000242	0.00387	CbGeAlD
Fluoxetine—HTR2A—midbrain—brain cancer	0.000231	0.00371	CbGeAlD
Fluoxetine—HTR2A—spinal cord—brain cancer	0.000225	0.00362	CbGeAlD
Fluoxetine—CYP2B6—central nervous system—brain cancer	0.000224	0.0036	CbGeAlD
Fluoxetine—ABCB1—telencephalon—brain cancer	0.000211	0.00338	CbGeAlD
Fluoxetine—HTR2A—endocrine gland—brain cancer	0.000203	0.00325	CbGeAlD
Fluoxetine—Alopecia—Hydroxyurea—brain cancer	0.0002	0.00116	CcSEcCtD
Fluoxetine—HTR2A—head—brain cancer	0.0002	0.00321	CbGeAlD
Fluoxetine—Weight decreased—Temozolomide—brain cancer	0.0002	0.00116	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Carmustine—brain cancer	0.0002	0.00116	CcSEcCtD
Fluoxetine—Hyperglycaemia—Temozolomide—brain cancer	0.0002	0.00116	CcSEcCtD
Fluoxetine—Stomatitis—Carmustine—brain cancer	0.000199	0.00115	CcSEcCtD
Fluoxetine—Urinary tract infection—Carmustine—brain cancer	0.000199	0.00115	CcSEcCtD
Fluoxetine—Pneumonia—Temozolomide—brain cancer	0.000199	0.00115	CcSEcCtD
Fluoxetine—Anorexia—Procarbazine—brain cancer	0.000199	0.00115	CcSEcCtD
Fluoxetine—Depression—Temozolomide—brain cancer	0.000197	0.00114	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.000196	0.00113	CcSEcCtD
Fluoxetine—Cardiac arrest—Etoposide—brain cancer	0.000195	0.00113	CcSEcCtD
Fluoxetine—Nausea—Lomustine—brain cancer	0.000195	0.00113	CcSEcCtD
Fluoxetine—Hypotension—Procarbazine—brain cancer	0.000195	0.00113	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Temozolomide—brain cancer	0.000194	0.00112	CcSEcCtD
Fluoxetine—Stomatitis—Temozolomide—brain cancer	0.000192	0.00111	CcSEcCtD
Fluoxetine—Urinary tract infection—Temozolomide—brain cancer	0.000192	0.00111	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00019	0.0011	CcSEcCtD
Fluoxetine—Insomnia—Procarbazine—brain cancer	0.000188	0.00109	CcSEcCtD
Fluoxetine—CYP3A4—endocrine gland—brain cancer	0.000188	0.00301	CbGeAlD
Fluoxetine—Paraesthesia—Procarbazine—brain cancer	0.000187	0.00108	CcSEcCtD
Fluoxetine—Sinusitis—Temozolomide—brain cancer	0.000185	0.00107	CcSEcCtD
Fluoxetine—Somnolence—Procarbazine—brain cancer	0.000185	0.00107	CcSEcCtD
Fluoxetine—CYP2D6—endocrine gland—brain cancer	0.000185	0.00296	CbGeAlD
Fluoxetine—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000185	0.00107	CcSEcCtD
Fluoxetine—Haemoglobin—Carmustine—brain cancer	0.000184	0.00107	CcSEcCtD
Fluoxetine—Haemorrhage—Carmustine—brain cancer	0.000183	0.00106	CcSEcCtD
Fluoxetine—Ill-defined disorder—Hydroxyurea—brain cancer	0.000183	0.00106	CcSEcCtD
Fluoxetine—HTR2A—central nervous system—brain cancer	0.000183	0.00293	CbGeAlD
Fluoxetine—Anaemia—Hydroxyurea—brain cancer	0.000183	0.00106	CcSEcCtD
Fluoxetine—CYP2D6—head—brain cancer	0.000182	0.00293	CbGeAlD
Fluoxetine—Hypoaesthesia—Carmustine—brain cancer	0.000182	0.00106	CcSEcCtD
Fluoxetine—Hallucination—Carmustine—brain cancer	0.000182	0.00106	CcSEcCtD
Fluoxetine—Decreased appetite—Procarbazine—brain cancer	0.000181	0.00105	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Etoposide—brain cancer	0.000181	0.00105	CcSEcCtD
Fluoxetine—Oedema peripheral—Carmustine—brain cancer	0.000181	0.00105	CcSEcCtD
Fluoxetine—Fatigue—Procarbazine—brain cancer	0.00018	0.00104	CcSEcCtD
Fluoxetine—HTR2A—cerebellum—brain cancer	0.000179	0.00287	CbGeAlD
Fluoxetine—Haemoglobin—Temozolomide—brain cancer	0.000178	0.00103	CcSEcCtD
Fluoxetine—Malaise—Hydroxyurea—brain cancer	0.000178	0.00103	CcSEcCtD
Fluoxetine—Constipation—Procarbazine—brain cancer	0.000178	0.00103	CcSEcCtD
Fluoxetine—Pain—Procarbazine—brain cancer	0.000178	0.00103	CcSEcCtD
Fluoxetine—CYP2B6—brain—brain cancer	0.000178	0.00285	CbGeAlD
Fluoxetine—Hepatitis—Temozolomide—brain cancer	0.000177	0.00103	CcSEcCtD
Fluoxetine—Haemorrhage—Temozolomide—brain cancer	0.000177	0.00103	CcSEcCtD
Fluoxetine—Dysphagia—Etoposide—brain cancer	0.000177	0.00103	CcSEcCtD
Fluoxetine—Leukopenia—Hydroxyurea—brain cancer	0.000177	0.00102	CcSEcCtD
Fluoxetine—Visual impairment—Carmustine—brain cancer	0.000177	0.00102	CcSEcCtD
Fluoxetine—Hypoaesthesia—Temozolomide—brain cancer	0.000176	0.00102	CcSEcCtD
Fluoxetine—Hallucination—Temozolomide—brain cancer	0.000176	0.00102	CcSEcCtD
Fluoxetine—ABCB1—gonad—brain cancer	0.000176	0.00282	CbGeAlD
Fluoxetine—Pharyngitis—Temozolomide—brain cancer	0.000176	0.00102	CcSEcCtD
Fluoxetine—Oedema peripheral—Temozolomide—brain cancer	0.000175	0.00101	CcSEcCtD
Fluoxetine—Bronchospasm—Etoposide—brain cancer	0.000174	0.00101	CcSEcCtD
Fluoxetine—Sweating increased—Etoposide—brain cancer	0.000173	0.000999	CcSEcCtD
Fluoxetine—ABCB1—pituitary gland—brain cancer	0.000172	0.00275	CbGeAlD
Fluoxetine—Feeling abnormal—Procarbazine—brain cancer	0.000172	0.000994	CcSEcCtD
Fluoxetine—Convulsion—Hydroxyurea—brain cancer	0.000171	0.000991	CcSEcCtD
Fluoxetine—Visual impairment—Temozolomide—brain cancer	0.000171	0.000989	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Procarbazine—brain cancer	0.00017	0.000986	CcSEcCtD
Fluoxetine—CYP3A4—central nervous system—brain cancer	0.000169	0.00271	CbGeAlD
Fluoxetine—Pancytopenia—Etoposide—brain cancer	0.000168	0.000974	CcSEcCtD
Fluoxetine—Erythema multiforme—Temozolomide—brain cancer	0.000168	0.00097	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000167	0.000967	CcSEcCtD
Fluoxetine—CYP2D6—central nervous system—brain cancer	0.000167	0.00267	CbGeAlD
Fluoxetine—Discomfort—Hydroxyurea—brain cancer	0.000166	0.000962	CcSEcCtD
Fluoxetine—ABCB1—medulla oblongata—brain cancer	0.000166	0.00266	CbGeAlD
Fluoxetine—Urticaria—Procarbazine—brain cancer	0.000165	0.000958	CcSEcCtD
Fluoxetine—Tinnitus—Temozolomide—brain cancer	0.000165	0.000957	CcSEcCtD
Fluoxetine—Body temperature increased—Procarbazine—brain cancer	0.000165	0.000953	CcSEcCtD
Fluoxetine—Abdominal pain—Procarbazine—brain cancer	0.000165	0.000953	CcSEcCtD
Fluoxetine—Arrhythmia—Carmustine—brain cancer	0.000164	0.000949	CcSEcCtD
Fluoxetine—CYP2D6—cerebellum—brain cancer	0.000163	0.00261	CbGeAlD
Fluoxetine—Alopecia—Carmustine—brain cancer	0.000162	0.000938	CcSEcCtD
Fluoxetine—Mental disorder—Carmustine—brain cancer	0.000161	0.00093	CcSEcCtD
Fluoxetine—Infection—Hydroxyurea—brain cancer	0.00016	0.000927	CcSEcCtD
Fluoxetine—Malnutrition—Carmustine—brain cancer	0.00016	0.000924	CcSEcCtD
Fluoxetine—Chills—Temozolomide—brain cancer	0.000159	0.000921	CcSEcCtD
Fluoxetine—Pneumonia—Etoposide—brain cancer	0.000159	0.00092	CcSEcCtD
Fluoxetine—Thrombocytopenia—Hydroxyurea—brain cancer	0.000158	0.000914	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000157	0.000907	CcSEcCtD
Fluoxetine—Alopecia—Temozolomide—brain cancer	0.000157	0.000907	CcSEcCtD
Fluoxetine—Skin disorder—Hydroxyurea—brain cancer	0.000157	0.000907	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Etoposide—brain cancer	0.000156	0.000902	CcSEcCtD
Fluoxetine—Renal failure—Etoposide—brain cancer	0.000155	0.000899	CcSEcCtD
Fluoxetine—Mental disorder—Temozolomide—brain cancer	0.000155	0.000899	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Etoposide—brain cancer	0.000155	0.000897	CcSEcCtD
Fluoxetine—Myocardial infarction—Etoposide—brain cancer	0.000155	0.000897	CcSEcCtD
Fluoxetine—Back pain—Carmustine—brain cancer	0.000154	0.000894	CcSEcCtD
Fluoxetine—Malnutrition—Temozolomide—brain cancer	0.000154	0.000893	CcSEcCtD
Fluoxetine—Jaundice—Etoposide—brain cancer	0.000154	0.000892	CcSEcCtD
Fluoxetine—Stomatitis—Etoposide—brain cancer	0.000154	0.000892	CcSEcCtD
Fluoxetine—Anorexia—Hydroxyurea—brain cancer	0.000154	0.00089	CcSEcCtD
Fluoxetine—Hypersensitivity—Procarbazine—brain cancer	0.000153	0.000888	CcSEcCtD
Fluoxetine—ABCB1—midbrain—brain cancer	0.000151	0.00243	CbGeAlD
Fluoxetine—Dysgeusia—Temozolomide—brain cancer	0.000151	0.000875	CcSEcCtD
Fluoxetine—Tremor—Carmustine—brain cancer	0.00015	0.000866	CcSEcCtD
Fluoxetine—Asthenia—Procarbazine—brain cancer	0.000149	0.000865	CcSEcCtD
Fluoxetine—Back pain—Temozolomide—brain cancer	0.000149	0.000864	CcSEcCtD
Fluoxetine—ABCB1—spinal cord—brain cancer	0.000148	0.00237	CbGeAlD
Fluoxetine—Anaemia—Carmustine—brain cancer	0.000148	0.000854	CcSEcCtD
Fluoxetine—Pruritus—Procarbazine—brain cancer	0.000147	0.000853	CcSEcCtD
Fluoxetine—Agitation—Carmustine—brain cancer	0.000147	0.00085	CcSEcCtD
Fluoxetine—HTR2A—brain—brain cancer	0.000145	0.00233	CbGeAlD
Fluoxetine—Tremor—Temozolomide—brain cancer	0.000145	0.000837	CcSEcCtD
Fluoxetine—Dyspnoea—Hydroxyurea—brain cancer	0.000144	0.000832	CcSEcCtD
Fluoxetine—Somnolence—Hydroxyurea—brain cancer	0.000143	0.00083	CcSEcCtD
Fluoxetine—Ill-defined disorder—Temozolomide—brain cancer	0.000143	0.000829	CcSEcCtD
Fluoxetine—Leukopenia—Carmustine—brain cancer	0.000143	0.000827	CcSEcCtD
Fluoxetine—Anaemia—Temozolomide—brain cancer	0.000143	0.000826	CcSEcCtD
Fluoxetine—Diarrhoea—Procarbazine—brain cancer	0.000142	0.000825	CcSEcCtD
Fluoxetine—Dyspepsia—Hydroxyurea—brain cancer	0.000142	0.000822	CcSEcCtD
Fluoxetine—Agitation—Temozolomide—brain cancer	0.000142	0.000821	CcSEcCtD
Fluoxetine—Hypoaesthesia—Etoposide—brain cancer	0.000141	0.000817	CcSEcCtD
Fluoxetine—Angioedema—Temozolomide—brain cancer	0.000141	0.000816	CcSEcCtD
Fluoxetine—Decreased appetite—Hydroxyurea—brain cancer	0.00014	0.000811	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000139	0.000806	CcSEcCtD
Fluoxetine—Malaise—Temozolomide—brain cancer	0.000139	0.000806	CcSEcCtD
Fluoxetine—Fatigue—Hydroxyurea—brain cancer	0.000139	0.000805	CcSEcCtD
Fluoxetine—Vertigo—Temozolomide—brain cancer	0.000139	0.000803	CcSEcCtD
Fluoxetine—Convulsion—Carmustine—brain cancer	0.000138	0.000801	CcSEcCtD
Fluoxetine—Leukopenia—Temozolomide—brain cancer	0.000138	0.0008	CcSEcCtD
Fluoxetine—Hypertension—Carmustine—brain cancer	0.000138	0.000798	CcSEcCtD
Fluoxetine—Pain—Hydroxyurea—brain cancer	0.000138	0.000798	CcSEcCtD
Fluoxetine—Constipation—Hydroxyurea—brain cancer	0.000138	0.000798	CcSEcCtD
Fluoxetine—Dizziness—Procarbazine—brain cancer	0.000138	0.000797	CcSEcCtD
Fluoxetine—Palpitations—Temozolomide—brain cancer	0.000136	0.000789	CcSEcCtD
Fluoxetine—Myalgia—Carmustine—brain cancer	0.000136	0.000787	CcSEcCtD
Fluoxetine—Chest pain—Carmustine—brain cancer	0.000136	0.000787	CcSEcCtD
Fluoxetine—Anxiety—Carmustine—brain cancer	0.000135	0.000784	CcSEcCtD
Fluoxetine—Cough—Temozolomide—brain cancer	0.000135	0.00078	CcSEcCtD
Fluoxetine—Erythema multiforme—Etoposide—brain cancer	0.000134	0.000776	CcSEcCtD
Fluoxetine—Convulsion—Temozolomide—brain cancer	0.000134	0.000774	CcSEcCtD
Fluoxetine—Hypertension—Temozolomide—brain cancer	0.000133	0.000771	CcSEcCtD
Fluoxetine—ABCB1—endocrine gland—brain cancer	0.000133	0.00213	CbGeAlD
Fluoxetine—Feeling abnormal—Hydroxyurea—brain cancer	0.000133	0.000769	CcSEcCtD
Fluoxetine—Vomiting—Procarbazine—brain cancer	0.000132	0.000767	CcSEcCtD
Fluoxetine—CYP2D6—brain—brain cancer	0.000132	0.00212	CbGeAlD
Fluoxetine—Confusional state—Carmustine—brain cancer	0.000131	0.000761	CcSEcCtD
Fluoxetine—Myalgia—Temozolomide—brain cancer	0.000131	0.000761	CcSEcCtD
Fluoxetine—Arthralgia—Temozolomide—brain cancer	0.000131	0.000761	CcSEcCtD
Fluoxetine—Rash—Procarbazine—brain cancer	0.000131	0.00076	CcSEcCtD
Fluoxetine—ABCB1—head—brain cancer	0.000131	0.00211	CbGeAlD
Fluoxetine—Dermatitis—Procarbazine—brain cancer	0.000131	0.00076	CcSEcCtD
Fluoxetine—Anxiety—Temozolomide—brain cancer	0.000131	0.000758	CcSEcCtD
Fluoxetine—Headache—Procarbazine—brain cancer	0.00013	0.000755	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.00013	0.000755	CcSEcCtD
Fluoxetine—Discomfort—Temozolomide—brain cancer	0.00013	0.000751	CcSEcCtD
Fluoxetine—Infection—Carmustine—brain cancer	0.000129	0.00075	CcSEcCtD
Fluoxetine—Dry mouth—Temozolomide—brain cancer	0.000128	0.000744	CcSEcCtD
Fluoxetine—Thrombocytopenia—Carmustine—brain cancer	0.000128	0.000739	CcSEcCtD
Fluoxetine—Body temperature increased—Hydroxyurea—brain cancer	0.000127	0.000738	CcSEcCtD
Fluoxetine—Chills—Etoposide—brain cancer	0.000127	0.000737	CcSEcCtD
Fluoxetine—Tachycardia—Carmustine—brain cancer	0.000127	0.000736	CcSEcCtD
Fluoxetine—Confusional state—Temozolomide—brain cancer	0.000127	0.000735	CcSEcCtD
Fluoxetine—Anaphylactic shock—Temozolomide—brain cancer	0.000126	0.000729	CcSEcCtD
Fluoxetine—Alopecia—Etoposide—brain cancer	0.000125	0.000726	CcSEcCtD
Fluoxetine—Infection—Temozolomide—brain cancer	0.000125	0.000724	CcSEcCtD
Fluoxetine—Anorexia—Carmustine—brain cancer	0.000124	0.000719	CcSEcCtD
Fluoxetine—Nausea—Procarbazine—brain cancer	0.000124	0.000716	CcSEcCtD
Fluoxetine—Thrombocytopenia—Temozolomide—brain cancer	0.000123	0.000714	CcSEcCtD
Fluoxetine—Skin disorder—Temozolomide—brain cancer	0.000122	0.000708	CcSEcCtD
Fluoxetine—Hypotension—Carmustine—brain cancer	0.000122	0.000705	CcSEcCtD
Fluoxetine—Hyperhidrosis—Temozolomide—brain cancer	0.000122	0.000705	CcSEcCtD
Fluoxetine—Dysgeusia—Etoposide—brain cancer	0.000121	0.0007	CcSEcCtD
Fluoxetine—Anorexia—Temozolomide—brain cancer	0.00012	0.000695	CcSEcCtD
Fluoxetine—ABCB1—central nervous system—brain cancer	0.00012	0.00192	CbGeAlD
Fluoxetine—Back pain—Etoposide—brain cancer	0.000119	0.000691	CcSEcCtD
Fluoxetine—Hypersensitivity—Hydroxyurea—brain cancer	0.000119	0.000688	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Carmustine—brain cancer	0.000119	0.000687	CcSEcCtD
Fluoxetine—Muscle spasms—Etoposide—brain cancer	0.000119	0.000687	CcSEcCtD
Fluoxetine—Insomnia—Carmustine—brain cancer	0.000118	0.000682	CcSEcCtD
Fluoxetine—ABCB1—cerebellum—brain cancer	0.000117	0.00188	CbGeAlD
Fluoxetine—Paraesthesia—Carmustine—brain cancer	0.000117	0.000677	CcSEcCtD
Fluoxetine—Dyspnoea—Carmustine—brain cancer	0.000116	0.000673	CcSEcCtD
Fluoxetine—Somnolence—Carmustine—brain cancer	0.000116	0.000671	CcSEcCtD
Fluoxetine—Asthenia—Hydroxyurea—brain cancer	0.000116	0.00067	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000115	0.000664	CcSEcCtD
Fluoxetine—Ill-defined disorder—Etoposide—brain cancer	0.000115	0.000663	CcSEcCtD
Fluoxetine—Anaemia—Etoposide—brain cancer	0.000114	0.000661	CcSEcCtD
Fluoxetine—Insomnia—Temozolomide—brain cancer	0.000114	0.000659	CcSEcCtD
Fluoxetine—Decreased appetite—Carmustine—brain cancer	0.000113	0.000656	CcSEcCtD
Fluoxetine—Paraesthesia—Temozolomide—brain cancer	0.000113	0.000655	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Carmustine—brain cancer	0.000112	0.000651	CcSEcCtD
Fluoxetine—Dyspnoea—Temozolomide—brain cancer	0.000112	0.00065	CcSEcCtD
Fluoxetine—Somnolence—Temozolomide—brain cancer	0.000112	0.000648	CcSEcCtD
Fluoxetine—Pain—Carmustine—brain cancer	0.000111	0.000645	CcSEcCtD
Fluoxetine—Constipation—Carmustine—brain cancer	0.000111	0.000645	CcSEcCtD
Fluoxetine—Malaise—Etoposide—brain cancer	0.000111	0.000645	CcSEcCtD
Fluoxetine—Vertigo—Etoposide—brain cancer	0.000111	0.000642	CcSEcCtD
Fluoxetine—Dyspepsia—Temozolomide—brain cancer	0.000111	0.000642	CcSEcCtD
Fluoxetine—Leukopenia—Etoposide—brain cancer	0.000111	0.00064	CcSEcCtD
Fluoxetine—Diarrhoea—Hydroxyurea—brain cancer	0.00011	0.000639	CcSEcCtD
Fluoxetine—Decreased appetite—Temozolomide—brain cancer	0.000109	0.000634	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Temozolomide—brain cancer	0.000109	0.000629	CcSEcCtD
Fluoxetine—Fatigue—Temozolomide—brain cancer	0.000109	0.000629	CcSEcCtD
Fluoxetine—Loss of consciousness—Etoposide—brain cancer	0.000109	0.000628	CcSEcCtD
Fluoxetine—Cough—Etoposide—brain cancer	0.000108	0.000624	CcSEcCtD
Fluoxetine—Pain—Temozolomide—brain cancer	0.000108	0.000623	CcSEcCtD
Fluoxetine—Constipation—Temozolomide—brain cancer	0.000108	0.000623	CcSEcCtD
Fluoxetine—Feeling abnormal—Carmustine—brain cancer	0.000107	0.000622	CcSEcCtD
Fluoxetine—Convulsion—Etoposide—brain cancer	0.000107	0.000619	CcSEcCtD
Fluoxetine—Hypertension—Etoposide—brain cancer	0.000107	0.000617	CcSEcCtD
Fluoxetine—Dizziness—Hydroxyurea—brain cancer	0.000107	0.000617	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Carmustine—brain cancer	0.000107	0.000617	CcSEcCtD
Fluoxetine—Chest pain—Etoposide—brain cancer	0.000105	0.000609	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000104	0.000604	CcSEcCtD
Fluoxetine—Discomfort—Etoposide—brain cancer	0.000104	0.000601	CcSEcCtD
Fluoxetine—Feeling abnormal—Temozolomide—brain cancer	0.000104	0.000601	CcSEcCtD
Fluoxetine—Abdominal pain—Carmustine—brain cancer	0.000103	0.000596	CcSEcCtD
Fluoxetine—Body temperature increased—Carmustine—brain cancer	0.000103	0.000596	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Temozolomide—brain cancer	0.000103	0.000596	CcSEcCtD
Fluoxetine—Vomiting—Hydroxyurea—brain cancer	0.000102	0.000593	CcSEcCtD
Fluoxetine—Rash—Hydroxyurea—brain cancer	0.000102	0.000588	CcSEcCtD
Fluoxetine—Confusional state—Etoposide—brain cancer	0.000102	0.000588	CcSEcCtD
Fluoxetine—Dermatitis—Hydroxyurea—brain cancer	0.000102	0.000588	CcSEcCtD
Fluoxetine—Headache—Hydroxyurea—brain cancer	0.000101	0.000585	CcSEcCtD
Fluoxetine—Anaphylactic shock—Etoposide—brain cancer	0.000101	0.000583	CcSEcCtD
Fluoxetine—Infection—Etoposide—brain cancer	0.0001	0.00058	CcSEcCtD
Fluoxetine—Urticaria—Temozolomide—brain cancer	0.0001	0.000579	CcSEcCtD
Fluoxetine—Abdominal pain—Temozolomide—brain cancer	9.95e-05	0.000576	CcSEcCtD
Fluoxetine—Body temperature increased—Temozolomide—brain cancer	9.95e-05	0.000576	CcSEcCtD
Fluoxetine—Thrombocytopenia—Etoposide—brain cancer	9.86e-05	0.000571	CcSEcCtD
Fluoxetine—Tachycardia—Etoposide—brain cancer	9.83e-05	0.000569	CcSEcCtD
Fluoxetine—Skin disorder—Etoposide—brain cancer	9.79e-05	0.000567	CcSEcCtD
Fluoxetine—Hyperhidrosis—Etoposide—brain cancer	9.74e-05	0.000564	CcSEcCtD
Fluoxetine—Anorexia—Etoposide—brain cancer	9.6e-05	0.000556	CcSEcCtD
Fluoxetine—Hypersensitivity—Carmustine—brain cancer	9.6e-05	0.000556	CcSEcCtD
Fluoxetine—Nausea—Hydroxyurea—brain cancer	9.57e-05	0.000554	CcSEcCtD
Fluoxetine—ABCB1—brain—brain cancer	9.51e-05	0.00153	CbGeAlD
Fluoxetine—Hypotension—Etoposide—brain cancer	9.41e-05	0.000545	CcSEcCtD
Fluoxetine—Asthenia—Carmustine—brain cancer	9.35e-05	0.000541	CcSEcCtD
Fluoxetine—Hypersensitivity—Temozolomide—brain cancer	9.28e-05	0.000537	CcSEcCtD
Fluoxetine—Paraesthesia—Etoposide—brain cancer	9.05e-05	0.000524	CcSEcCtD
Fluoxetine—Asthenia—Temozolomide—brain cancer	9.03e-05	0.000523	CcSEcCtD
Fluoxetine—Dyspnoea—Etoposide—brain cancer	8.98e-05	0.00052	CcSEcCtD
Fluoxetine—Somnolence—Etoposide—brain cancer	8.96e-05	0.000519	CcSEcCtD
Fluoxetine—Diarrhoea—Carmustine—brain cancer	8.91e-05	0.000516	CcSEcCtD
Fluoxetine—Pruritus—Temozolomide—brain cancer	8.91e-05	0.000516	CcSEcCtD
Fluoxetine—Decreased appetite—Etoposide—brain cancer	8.76e-05	0.000507	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Etoposide—brain cancer	8.7e-05	0.000504	CcSEcCtD
Fluoxetine—Fatigue—Etoposide—brain cancer	8.69e-05	0.000503	CcSEcCtD
Fluoxetine—Dizziness—Carmustine—brain cancer	8.62e-05	0.000499	CcSEcCtD
Fluoxetine—Pain—Etoposide—brain cancer	8.62e-05	0.000499	CcSEcCtD
Fluoxetine—Constipation—Etoposide—brain cancer	8.62e-05	0.000499	CcSEcCtD
Fluoxetine—Diarrhoea—Temozolomide—brain cancer	8.62e-05	0.000499	CcSEcCtD
Fluoxetine—Dizziness—Temozolomide—brain cancer	8.33e-05	0.000482	CcSEcCtD
Fluoxetine—Feeling abnormal—Etoposide—brain cancer	8.3e-05	0.000481	CcSEcCtD
Fluoxetine—Vomiting—Carmustine—brain cancer	8.28e-05	0.00048	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Etoposide—brain cancer	8.24e-05	0.000477	CcSEcCtD
Fluoxetine—Rash—Carmustine—brain cancer	8.22e-05	0.000476	CcSEcCtD
Fluoxetine—Dermatitis—Carmustine—brain cancer	8.21e-05	0.000475	CcSEcCtD
Fluoxetine—Headache—Carmustine—brain cancer	8.16e-05	0.000473	CcSEcCtD
Fluoxetine—Vomiting—Temozolomide—brain cancer	8.01e-05	0.000464	CcSEcCtD
Fluoxetine—Urticaria—Etoposide—brain cancer	8e-05	0.000463	CcSEcCtD
Fluoxetine—Abdominal pain—Etoposide—brain cancer	7.96e-05	0.000461	CcSEcCtD
Fluoxetine—Body temperature increased—Etoposide—brain cancer	7.96e-05	0.000461	CcSEcCtD
Fluoxetine—Rash—Temozolomide—brain cancer	7.94e-05	0.00046	CcSEcCtD
Fluoxetine—Dermatitis—Temozolomide—brain cancer	7.93e-05	0.000459	CcSEcCtD
Fluoxetine—Headache—Temozolomide—brain cancer	7.89e-05	0.000457	CcSEcCtD
Fluoxetine—Nausea—Carmustine—brain cancer	7.74e-05	0.000448	CcSEcCtD
Fluoxetine—Nausea—Temozolomide—brain cancer	7.48e-05	0.000433	CcSEcCtD
Fluoxetine—Hypersensitivity—Etoposide—brain cancer	7.42e-05	0.00043	CcSEcCtD
Fluoxetine—Asthenia—Etoposide—brain cancer	7.23e-05	0.000419	CcSEcCtD
Fluoxetine—Pruritus—Etoposide—brain cancer	7.13e-05	0.000413	CcSEcCtD
Fluoxetine—Diarrhoea—Etoposide—brain cancer	6.89e-05	0.000399	CcSEcCtD
Fluoxetine—Dizziness—Etoposide—brain cancer	6.66e-05	0.000386	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—PTCH2—brain cancer	6.55e-05	0.003	CbGpPWpGaD
Fluoxetine—HTR2C—G alpha (q) signalling events—TRPC6—brain cancer	6.45e-05	0.00295	CbGpPWpGaD
Fluoxetine—Vomiting—Etoposide—brain cancer	6.41e-05	0.000371	CcSEcCtD
Fluoxetine—CYP2D6—Biological oxidations—CYP2C9—brain cancer	6.37e-05	0.00292	CbGpPWpGaD
Fluoxetine—Rash—Etoposide—brain cancer	6.35e-05	0.000368	CcSEcCtD
Fluoxetine—Dermatitis—Etoposide—brain cancer	6.35e-05	0.000368	CcSEcCtD
Fluoxetine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	6.31e-05	0.00289	CbGpPWpGaD
Fluoxetine—Headache—Etoposide—brain cancer	6.31e-05	0.000365	CcSEcCtD
Fluoxetine—CYP2D6—Metapathway biotransformation—CYP2C9—brain cancer	6.28e-05	0.00288	CbGpPWpGaD
Fluoxetine—Nausea—Etoposide—brain cancer	5.98e-05	0.000347	CcSEcCtD
Fluoxetine—ALB—Folate Metabolism—SOD2—brain cancer	5.95e-05	0.00272	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—SIRT1—brain cancer	5.87e-05	0.00269	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—brain cancer	5.77e-05	0.00264	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—OR14C36—brain cancer	5.74e-05	0.00263	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—OR4C12—brain cancer	5.74e-05	0.00263	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—PTCH2—brain cancer	5.69e-05	0.0026	CbGpPWpGaD
Fluoxetine—HTR2A—G alpha (q) signalling events—TRPC6—brain cancer	5.6e-05	0.00256	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	5.57e-05	0.00255	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—CYP2C9—brain cancer	5.4e-05	0.00247	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—ESR2—brain cancer	5.37e-05	0.00246	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—CYP2C9—brain cancer	5.32e-05	0.00244	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—OR4C12—brain cancer	5.22e-05	0.00239	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—OR14C36—brain cancer	5.22e-05	0.00239	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—brain cancer	5.01e-05	0.00229	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—OR4C12—brain cancer	4.99e-05	0.00228	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—OR14C36—brain cancer	4.99e-05	0.00228	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—SOD2—brain cancer	4.73e-05	0.00216	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—OR4C12—brain cancer	4.53e-05	0.00207	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—OR14C36—brain cancer	4.53e-05	0.00207	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—CDK4—brain cancer	4.44e-05	0.00203	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—PDGFRA—brain cancer	4.31e-05	0.00197	CbGpPWpGaD
Fluoxetine—ALB—Vitamin B12 Metabolism—RELA—brain cancer	4.23e-05	0.00193	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—HES1—brain cancer	4.17e-05	0.00191	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—CYP2C9—brain cancer	4.16e-05	0.00191	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	4.11e-05	0.00188	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MPL—brain cancer	4.1e-05	0.00187	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—S100A10—brain cancer	3.93e-05	0.0018	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	3.59e-05	0.00164	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—TRPC6—brain cancer	3.52e-05	0.00161	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—brain cancer	3.48e-05	0.00159	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—RELA—brain cancer	3.44e-05	0.00157	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	3.41e-05	0.00156	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—S100A10—brain cancer	3.4e-05	0.00156	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—SHH—brain cancer	3.37e-05	0.00154	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PTCH2—brain cancer	3.36e-05	0.00154	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—RELA—brain cancer	3.21e-05	0.00147	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—PTCH1—brain cancer	3.2e-05	0.00146	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—SMO—brain cancer	3.2e-05	0.00146	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—TRPC6—brain cancer	3.12e-05	0.00143	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—IL2—brain cancer	3.1e-05	0.00142	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—OR14C36—brain cancer	3.08e-05	0.00141	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—OR4C12—brain cancer	3.08e-05	0.00141	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—brain cancer	3.06e-05	0.0014	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	2.98e-05	0.00136	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.96e-05	0.00136	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—SHH—brain cancer	2.93e-05	0.00134	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PTCH2—brain cancer	2.92e-05	0.00134	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—ABR—brain cancer	2.9e-05	0.00133	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	2.89e-05	0.00132	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	2.88e-05	0.00132	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—PTCH1—brain cancer	2.78e-05	0.00127	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—SMO—brain cancer	2.78e-05	0.00127	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—BSG—brain cancer	2.77e-05	0.00127	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—RELA—brain cancer	2.73e-05	0.00125	CbGpPWpGaD
Fluoxetine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	2.69e-05	0.00123	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—OR4C12—brain cancer	2.68e-05	0.00122	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—OR14C36—brain cancer	2.68e-05	0.00122	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.66e-05	0.00122	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—ABR—brain cancer	2.64e-05	0.00121	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—VAV1—brain cancer	2.64e-05	0.00121	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—DTX2—brain cancer	2.62e-05	0.0012	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—ABR—brain cancer	2.52e-05	0.00115	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	2.46e-05	0.00112	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	2.36e-05	0.00108	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—IL2—brain cancer	2.35e-05	0.00108	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	2.32e-05	0.00106	CbGpPWpGaD
Fluoxetine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	2.31e-05	0.00106	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—ABR—brain cancer	2.29e-05	0.00105	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	2.29e-05	0.00105	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—DTX2—brain cancer	2.27e-05	0.00104	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	2.26e-05	0.00103	CbGpPWpGaD
Fluoxetine—ALB—Platelet degranulation—VEGFA—brain cancer	2.26e-05	0.00103	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	2.21e-05	0.00101	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	2.21e-05	0.00101	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.17e-05	0.000991	CbGpPWpGaD
Fluoxetine—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—brain cancer	2.15e-05	0.000984	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	2.13e-05	0.000973	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—CTNNB1—brain cancer	2.09e-05	0.000958	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.07e-05	0.000948	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	2.03e-05	0.000927	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—VEGFA—brain cancer	2e-05	0.000914	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—TP53—brain cancer	1.99e-05	0.00091	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTCH2—brain cancer	1.99e-05	0.000909	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.94e-05	0.00089	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HES5—brain cancer	1.92e-05	0.00088	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—TP53—brain cancer	1.89e-05	0.000864	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STRADA—brain cancer	1.87e-05	0.000854	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—brain cancer	1.84e-05	0.000843	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—TRPC6—brain cancer	1.84e-05	0.000841	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TRPC6—brain cancer	1.81e-05	0.00083	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.77e-05	0.000811	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	1.75e-05	0.000801	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—SHH—brain cancer	1.73e-05	0.000792	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTCH2—brain cancer	1.72e-05	0.000789	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	1.67e-05	0.000766	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HES5—brain cancer	1.67e-05	0.000764	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—TRPC6—brain cancer	1.67e-05	0.000764	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	1.65e-05	0.000754	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PTCH1—brain cancer	1.64e-05	0.000751	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—SMO—brain cancer	1.64e-05	0.000751	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STRADA—brain cancer	1.62e-05	0.000742	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—TRPC6—brain cancer	1.6e-05	0.000731	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—TRPC6—brain cancer	1.57e-05	0.000719	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP2C9—brain cancer	1.57e-05	0.000717	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ABR—brain cancer	1.56e-05	0.000713	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP2C9—brain cancer	1.53e-05	0.000701	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.52e-05	0.000693	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GLI2—brain cancer	1.5e-05	0.000689	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—SHH—brain cancer	1.5e-05	0.000688	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	1.48e-05	0.000676	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—TRPC6—brain cancer	1.45e-05	0.000663	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PTCH1—brain cancer	1.43e-05	0.000652	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—SMO—brain cancer	1.43e-05	0.000652	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GLI1—brain cancer	1.41e-05	0.000647	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—VAV1—brain cancer	1.38e-05	0.00063	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	1.38e-05	0.00063	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VAV1—brain cancer	1.36e-05	0.000622	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ABR—brain cancer	1.35e-05	0.000619	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SUFU—brain cancer	1.34e-05	0.000614	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—BSG—brain cancer	1.33e-05	0.00061	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP2C9—brain cancer	1.32e-05	0.000604	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GLI2—brain cancer	1.31e-05	0.000598	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—BSG—brain cancer	1.3e-05	0.000596	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—GFAP—brain cancer	1.29e-05	0.000592	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	1.28e-05	0.000587	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	1.28e-05	0.000586	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—VAV1—brain cancer	1.25e-05	0.000572	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GLI1—brain cancer	1.23e-05	0.000562	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HEY1—brain cancer	1.23e-05	0.000561	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—DLL1—brain cancer	1.2e-05	0.00055	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—VAV1—brain cancer	1.2e-05	0.000547	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP2C9—brain cancer	1.18e-05	0.000542	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—IL2—brain cancer	1.18e-05	0.000539	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SUFU—brain cancer	1.16e-05	0.000533	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP2C9—brain cancer	1.16e-05	0.000529	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—IDH1—brain cancer	1.15e-05	0.000524	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	1.13e-05	0.000517	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—GFAP—brain cancer	1.12e-05	0.000514	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—BSG—brain cancer	1.12e-05	0.000513	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—IDH1—brain cancer	1.12e-05	0.000513	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	1.12e-05	0.000512	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP2C9—brain cancer	1.09e-05	0.000499	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—VAV1—brain cancer	1.09e-05	0.000497	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HEY1—brain cancer	1.07e-05	0.000487	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—DLL1—brain cancer	1.04e-05	0.000478	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SHH—brain cancer	1.02e-05	0.000468	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—BSG—brain cancer	1.01e-05	0.000461	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—VEGFA—brain cancer	1e-05	0.000458	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TRPC6—brain cancer	9.86e-06	0.000451	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	9.86e-06	0.000451	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—BSG—brain cancer	9.83e-06	0.00045	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTCH1—brain cancer	9.7e-06	0.000444	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SMO—brain cancer	9.7e-06	0.000444	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—IDH1—brain cancer	9.65e-06	0.000442	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—BSG—brain cancer	9.26e-06	0.000424	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP2C9—brain cancer	9.23e-06	0.000422	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—BSG—brain cancer	9.18e-06	0.00042	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	9.07e-06	0.000415	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ENO2—brain cancer	9.06e-06	0.000415	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SHH—brain cancer	8.88e-06	0.000406	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	8.87e-06	0.000406	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ENO2—brain cancer	8.86e-06	0.000405	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CG—brain cancer	8.75e-06	0.0004	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—IDH1—brain cancer	8.66e-06	0.000396	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CG—brain cancer	8.63e-06	0.000395	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TRPC6—brain cancer	8.56e-06	0.000392	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—IDH1—brain cancer	8.45e-06	0.000387	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SMO—brain cancer	8.42e-06	0.000385	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTCH1—brain cancer	8.42e-06	0.000385	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—IDH1—brain cancer	7.97e-06	0.000365	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CG—brain cancer	7.94e-06	0.000363	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—IDH1—brain cancer	7.9e-06	0.000361	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	7.86e-06	0.000359	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—BSG—brain cancer	7.85e-06	0.000359	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOTCH2—brain cancer	7.75e-06	0.000355	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ENO2—brain cancer	7.63e-06	0.000349	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CG—brain cancer	7.59e-06	0.000348	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	7.45e-06	0.000341	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VAV1—brain cancer	7.39e-06	0.000338	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2C9—brain cancer	7.12e-06	0.000326	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	7.05e-06	0.000323	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CG—brain cancer	6.9e-06	0.000316	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ENO2—brain cancer	6.85e-06	0.000313	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—IDH1—brain cancer	6.75e-06	0.000309	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH2—brain cancer	6.73e-06	0.000308	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ENO2—brain cancer	6.68e-06	0.000306	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	6.43e-06	0.000294	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VAV1—brain cancer	6.42e-06	0.000294	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HES1—brain cancer	6.35e-06	0.000291	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ENO2—brain cancer	6.3e-06	0.000288	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ENO2—brain cancer	6.24e-06	0.000286	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—IL2—brain cancer	6.15e-06	0.000282	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IL2—brain cancer	6.07e-06	0.000278	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—BSG—brain cancer	6.06e-06	0.000277	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PDGFRA—brain cancer	6.05e-06	0.000277	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SPP1—brain cancer	5.87e-06	0.000269	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL2—brain cancer	5.59e-06	0.000256	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HES1—brain cancer	5.52e-06	0.000253	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.49e-06	0.000251	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—IL2—brain cancer	5.34e-06	0.000245	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ENO2—brain cancer	5.33e-06	0.000244	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IRS2—brain cancer	5.31e-06	0.000243	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PDGFRA—brain cancer	5.25e-06	0.00024	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—IDH1—brain cancer	5.21e-06	0.000238	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—brain cancer	5.16e-06	0.000236	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SPP1—brain cancer	5.1e-06	0.000233	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL2—brain cancer	4.85e-06	0.000222	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APC—brain cancer	4.69e-06	0.000215	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CG—brain cancer	4.69e-06	0.000215	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IRS2—brain cancer	4.61e-06	0.000211	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—brain cancer	4.27e-06	0.000196	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CG—brain cancer	4.16e-06	0.00019	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ENO2—brain cancer	4.12e-06	0.000188	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APC—brain cancer	4.07e-06	0.000186	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CG—brain cancer	4.07e-06	0.000186	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CG—brain cancer	4.06e-06	0.000186	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—brain cancer	3.9e-06	0.000178	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—brain cancer	3.71e-06	0.00017	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RELA—brain cancer	3.67e-06	0.000168	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB2—brain cancer	3.64e-06	0.000167	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—brain cancer	3.5e-06	0.00016	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—brain cancer	3.3e-06	0.000151	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—brain cancer	3.22e-06	0.000147	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CTNNB1—brain cancer	3.19e-06	0.000146	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RELA—brain cancer	3.18e-06	0.000146	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB2—brain cancer	3.16e-06	0.000145	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—brain cancer	3.14e-06	0.000144	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—brain cancer	3.07e-06	0.00014	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—brain cancer	2.89e-06	0.000132	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—brain cancer	2.87e-06	0.000131	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—brain cancer	2.86e-06	0.000131	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—brain cancer	2.81e-06	0.000128	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—brain cancer	2.79e-06	0.000128	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—brain cancer	2.78e-06	0.000127	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CTNNB1—brain cancer	2.77e-06	0.000127	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—brain cancer	2.58e-06	0.000118	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—brain cancer	2.53e-06	0.000116	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—brain cancer	2.45e-06	0.000112	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—brain cancer	2.44e-06	0.000112	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—brain cancer	2.41e-06	0.00011	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—brain cancer	2.24e-06	0.000103	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—brain cancer	2.19e-06	0.0001	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—brain cancer	2.12e-06	9.7e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—brain cancer	1.89e-06	8.64e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—brain cancer	1.84e-06	8.43e-05	CbGpPWpGaD
